Novabay Pharmaceuticals (NBY) 0.75 $NBY
Investors look to Lighten Up on Shares of Novabay Pharmaceuticals, Shares Down 7.8% (NBY)
Comtex SmarTrend(R) - Tue Sep 16, 11:38AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's worst performing penny stocks, down 7.8% to $0.74 on 1.1x average daily volume. Thus far today, Novabay Pharmaceuticals has traded 528,000 shares, vs. average volume of 477,000 shares per day. The stock has underperformed the Dow (-7.8% to the Dow's 0.6%) and underperformed the S&P 500 (-7.8% to the S&P's 0.7%) during today's trading.
NovaBay Pharmaceuticals Will Feature i-Lid Cleanser for the First Time at Vision Expo West
Business Wire - Tue Sep 16, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be featuring its i-Lid(TM) Cleanser with Neutrox(TM) for the first time at the International Vision Expo & Conference.
Hispanic Heroes Honored in Fight Against "Flesh-Eating" Disease
PR Newswire - Mon Sep 15, 12:18PM CDT
During National Hispanic Heritage Month, the National Necrotizing Fasciitis Foundation (NNFF) is honoring the courage of two Hispanic patients in fighting life-threatening "flesh-eating" disease--and the contributions of the Hispanic doctor who has worked all his life to improving medical care for the disease, and who is now saving lives and limbs with a pioneering new approach.
Novabay Pharmaceuticals Up 8.0%, Penny Stock Attracts Attention (NBY)
Comtex SmarTrend(R) - Tue Sep 09, 11:38AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing penny stocks, up 8.0% to $0.96 on 1.1x average daily volume. Novabay Pharmaceuticals has traded 483,000 shares thus far today, vs. average volume of 459,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.3%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
Center Director of Omni Eye Surgery in New York City Describes a Promising New Product for the Management of Eyelid Disease in News Publication
PR Newswire - Tue Sep 09, 6:00AM CDT
Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Healthcare Conference
Business Wire - Fri Sep 05, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that Ron Najafi, Ph.D., Chairman and CEO, will present a company update at the Rodman & Renshaw Healthcare Conference, held September 8-10, 2014 in New York City. Dr. Najafi along with Tom Paulson, Chief Financial Officer will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
China's Food and Drug Administration has Cleared NovaBay's NeutroPhase Skin and Wound Cleanser for Sale throughout Mainland China by NovaBay's Partner, China Pioneer Pharma
Business Wire - Wed Sep 03, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, today announced that China's Food and Drug Administration has cleared NovaBay's NeutroPhase(R) Skin and Wound Cleanser for sale throughout mainland China. NovaBay will be shipping NeutroPhase to China in the fourth quarter of 2014 to support Pioneer's launch of the product in early 2015.
NovaBay Pharmaceuticals Adds Five Top Ophthalmologists to its Ophthalmic Advisory Board
Business Wire - Thu Aug 28, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that it has added four new members to its Ophthalmic Advisory Board (OAB), who will join the ten existing members of the board. The board oversees the development, marketing and medical use of NovaBay's i-Lid(TM) Cleanser and other eye care products.
Hot Stock: Novabay Pharmaceuticals, Shares Gain 13.5% (NBY)
Comtex SmarTrend(R) - Mon Aug 25, 10:37AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing penny stocks, up 13.5% to $0.84 on 1.2x average daily volume. Thus far today, Novabay Pharmaceuticals has traded 491,000 shares, vs. average volume of 422,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser Across the U.S.
Business Wire - Mon Aug 25, 6:00AM CDT
--i-Lid Cleanser is Formulated to Help the 40 Million Patients Who Suffer From Blepharitis and Dry Eye
Stock to Watch: Novabay Pharmaceuticals Down 5.0% (NBY)
Comtex SmarTrend(R) - Thu Aug 21, 11:37AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's worst performing penny stocks, down 5.0% to $0.77 on 1.8x average daily volume. Novabay Pharmaceuticals has traded 495,000 shares thus far today, vs. average volume of 268,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's 0.4%) and underperformed the S&P 500 (-5.0% to the S&P's 0.2%) during today's trading.
NovaBay updates results of NVC-422 Phase 2 for viral conjunctivitis
M2 - Thu Aug 21, 7:30AM CDT
Biotechnology company NovaBay Pharmaceuticals (NYSE MKT:NBY) on Wednesday provided the results of its NVC-422 Phase 2 global, multi-centred, randomissed study of adenoviral conjunctivitis in the US, India, Sri Lanka and Brazil.
Why NovaBay Pharmaceuticals (NBY) Stock Plummeted to a One-Year Low Today
at The Street - Wed Aug 20, 12:12PM CDT
NovaBay Pharmaceuticals (NBY) plummeted to a 52-week low Wednesday after the company announced its potential adenoviral conjunctivitis treatment did not meet its endpoints in a Phase 2 clinical study.
Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease'
PR Newswire - Wed Aug 20, 11:19AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today announced that a patient named Fernando Davila has been successfully treated for a life threatening form of necrotizing fasciitis, or "flesh eating disease", by Dr, Anibal R. Gauto, Medical Director of Inpatient Wound Care and founder of The Wound Care Center, at Eisenhower Medical Center in Rancho Mirage, California.
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis
Business Wire - Wed Aug 20, 6:00AM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.
Traders Get Bullish on Shares of Novabay Pharmaceuticals, Shares Up 13.6% (NBY)
Comtex SmarTrend(R) - Mon Aug 18, 11:01AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing low-priced stocks, up 13.6% to $1.17 on 5.5x average daily volume. Novabay Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 203,000 shares per day. The stock has outperformed the Dow (13.6% to the Dow's 0.9%) and outperformed the S&P 500 (13.6% to the S&P's 0.8%) during today's trading.
National Necrotizing Fasciitis Foundation Warns Watch Out For Vibrio Infections
PR Newswire - Tue Aug 12, 9:00AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today issued a public service alert about a potentially deadly bacterium called Vibrio vulnificus. "This microbe can get into the body through a tiny cut in the skin, causing a life-threatening infection," explained Jacqueline Roemmele, executive director of the NNFF. "People who might come in contact with Vibrio need to know what to look for so that they can get immediate treatment."
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update
Business Wire - Thu Jul 31, 7:05AM CDT
--Advanced i-Lid Cleanser Introduced at the American Society of Cataract and Refractive Surgery in April 2014 with US Commercial Launch Planned for Q3, 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease
PR Newswire - Thu Jul 24, 8:40AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today is calling attention to an interview on RadioMD with Dr. John Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California. The subject: A new treatment for deadly flesh-eating disease, or necrotizing fasciitis.
Investors look to Lighten Up on Shares of Novabay Pharmaceuticals, Shares Down 7.8% (NBY)
Comtex SmarTrend(R) - Tue Sep 16, 11:38AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's worst performing penny stocks, down 7.8% to $0.74 on 1.1x average daily volume. Thus far today, Novabay Pharmaceuticals has traded 528,000 shares, vs. average volume of 477,000 shares per day. The stock has underperformed the Dow (-7.8% to the Dow's 0.6%) and underperformed the S&P 500 (-7.8% to the S&P's 0.7%) during today's trading.
NovaBay Pharmaceuticals Will Feature i-Lid Cleanser for the First Time at Vision Expo West
Business Wire - Tue Sep 16, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be featuring its i-Lid(TM) Cleanser with Neutrox(TM) for the first time at the International Vision Expo & Conference.
Hispanic Heroes Honored in Fight Against "Flesh-Eating" Disease
PR Newswire - Mon Sep 15, 12:18PM CDT
During National Hispanic Heritage Month, the National Necrotizing Fasciitis Foundation (NNFF) is honoring the courage of two Hispanic patients in fighting life-threatening "flesh-eating" disease--and the contributions of the Hispanic doctor who has worked all his life to improving medical care for the disease, and who is now saving lives and limbs with a pioneering new approach.
Novabay Pharmaceuticals Up 8.0%, Penny Stock Attracts Attention (NBY)
Comtex SmarTrend(R) - Tue Sep 09, 11:38AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing penny stocks, up 8.0% to $0.96 on 1.1x average daily volume. Novabay Pharmaceuticals has traded 483,000 shares thus far today, vs. average volume of 459,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.3%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
Center Director of Omni Eye Surgery in New York City Describes a Promising New Product for the Management of Eyelid Disease in News Publication
PR Newswire - Tue Sep 09, 6:00AM CDT
Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Healthcare Conference
Business Wire - Fri Sep 05, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that Ron Najafi, Ph.D., Chairman and CEO, will present a company update at the Rodman & Renshaw Healthcare Conference, held September 8-10, 2014 in New York City. Dr. Najafi along with Tom Paulson, Chief Financial Officer will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
China's Food and Drug Administration has Cleared NovaBay's NeutroPhase Skin and Wound Cleanser for Sale throughout Mainland China by NovaBay's Partner, China Pioneer Pharma
Business Wire - Wed Sep 03, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, today announced that China's Food and Drug Administration has cleared NovaBay's NeutroPhase(R) Skin and Wound Cleanser for sale throughout mainland China. NovaBay will be shipping NeutroPhase to China in the fourth quarter of 2014 to support Pioneer's launch of the product in early 2015.
NovaBay Pharmaceuticals Adds Five Top Ophthalmologists to its Ophthalmic Advisory Board
Business Wire - Thu Aug 28, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that it has added four new members to its Ophthalmic Advisory Board (OAB), who will join the ten existing members of the board. The board oversees the development, marketing and medical use of NovaBay's i-Lid(TM) Cleanser and other eye care products.
Hot Stock: Novabay Pharmaceuticals, Shares Gain 13.5% (NBY)
Comtex SmarTrend(R) - Mon Aug 25, 10:37AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing penny stocks, up 13.5% to $0.84 on 1.2x average daily volume. Thus far today, Novabay Pharmaceuticals has traded 491,000 shares, vs. average volume of 422,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser Across the U.S.
Business Wire - Mon Aug 25, 6:00AM CDT
--i-Lid Cleanser is Formulated to Help the 40 Million Patients Who Suffer From Blepharitis and Dry Eye
Stock to Watch: Novabay Pharmaceuticals Down 5.0% (NBY)
Comtex SmarTrend(R) - Thu Aug 21, 11:37AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's worst performing penny stocks, down 5.0% to $0.77 on 1.8x average daily volume. Novabay Pharmaceuticals has traded 495,000 shares thus far today, vs. average volume of 268,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's 0.4%) and underperformed the S&P 500 (-5.0% to the S&P's 0.2%) during today's trading.
NovaBay updates results of NVC-422 Phase 2 for viral conjunctivitis
M2 - Thu Aug 21, 7:30AM CDT
Biotechnology company NovaBay Pharmaceuticals (NYSE MKT:NBY) on Wednesday provided the results of its NVC-422 Phase 2 global, multi-centred, randomissed study of adenoviral conjunctivitis in the US, India, Sri Lanka and Brazil.
Why NovaBay Pharmaceuticals (NBY) Stock Plummeted to a One-Year Low Today
at The Street - Wed Aug 20, 12:12PM CDT
NovaBay Pharmaceuticals (NBY) plummeted to a 52-week low Wednesday after the company announced its potential adenoviral conjunctivitis treatment did not meet its endpoints in a Phase 2 clinical study.
Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease'
PR Newswire - Wed Aug 20, 11:19AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today announced that a patient named Fernando Davila has been successfully treated for a life threatening form of necrotizing fasciitis, or "flesh eating disease", by Dr, Anibal R. Gauto, Medical Director of Inpatient Wound Care and founder of The Wound Care Center, at Eisenhower Medical Center in Rancho Mirage, California.
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis
Business Wire - Wed Aug 20, 6:00AM CDT
NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.
Traders Get Bullish on Shares of Novabay Pharmaceuticals, Shares Up 13.6% (NBY)
Comtex SmarTrend(R) - Mon Aug 18, 11:01AM CDT
Novabay Pharmaceuticals (AMEX:NBY) is one of today's best performing low-priced stocks, up 13.6% to $1.17 on 5.5x average daily volume. Novabay Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 203,000 shares per day. The stock has outperformed the Dow (13.6% to the Dow's 0.9%) and outperformed the S&P 500 (13.6% to the S&P's 0.8%) during today's trading.
National Necrotizing Fasciitis Foundation Warns Watch Out For Vibrio Infections
PR Newswire - Tue Aug 12, 9:00AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today issued a public service alert about a potentially deadly bacterium called Vibrio vulnificus. "This microbe can get into the body through a tiny cut in the skin, causing a life-threatening infection," explained Jacqueline Roemmele, executive director of the NNFF. "People who might come in contact with Vibrio need to know what to look for so that they can get immediate treatment."
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update
Business Wire - Thu Jul 31, 7:05AM CDT
--Advanced i-Lid Cleanser Introduced at the American Society of Cataract and Refractive Surgery in April 2014 with US Commercial Launch Planned for Q3, 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease
PR Newswire - Thu Jul 24, 8:40AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today is calling attention to an interview on RadioMD with Dr. John Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California. The subject: A new treatment for deadly flesh-eating disease, or necrotizing fasciitis.
